Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P00749
UPID:
UROK_HUMAN
Alternative names:
-
Alternative UPACC:
P00749; B4DPZ2; Q15844; Q16618; Q53XS3; Q5SWW9; Q969W6
Background:
The Urokinase-type plasminogen activator (UPA), encoded by the gene with accession number P00749, plays a pivotal role in the fibrinolysis system by specifically converting the zymogen plasminogen into the active enzyme plasmin. This process is crucial for the breakdown of blood clots and maintaining vascular health.
Therapeutic significance:
UPA's aberrant activity is linked to Quebec platelet disorder, a bleeding condition characterized by excessive PLAU levels within platelets, leading to abnormal fibrinolysis. Targeting UPA's function or its dysregulation offers a promising avenue for developing treatments for this disorder and potentially other fibrinolysis-related conditions.